We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Pathologists Collaborate to Improve Reporting and Accessibility of Cancer Pathology Findings

By LabMedica International staff writers
Posted on 28 Oct 2013
A new partnership has been formed to provide an electronic application service to enhance cancer pathology reporting and use of datasets.

The College of American Pathologists (CAP; Northfield, IL, USA) and mTuitive, Inc. More...
(Centerville, MA, USA) have forged a collaboration to more effectively capture and report cancer pathology findings by providing a product and service that will facilitate production and use of standardized, encoded, and interoperable data sets for use in patient care, registries, research, and biorepositories.

Together, the CAP and mTuitive have developed “CAP eFRM” – the CAP electronic Forms and Reporting Module, an application incorporating the CAP electronic Cancer Checklists (eCC). Cancer case summaries within 65 cancer protocols are electronically represented within the eCC in addition to two new tumor biomarker reporting templates for colon and lung cancer. eFRM was now presented at the CAP’s annual meeting (CAP 2013, Orlando, FA, USA). “We designed eFRM to help pathologists and laboratories make more effective use of data electronically as they care for patients,” said Charles Roussel, CAP CEO; “This application eases eCC implementation for health care and laboratory system vendors, ultimately benefiting pathologists, laboratory professionals, clinicians, and patients.”

The American College of Surgeons - Commission on Cancer (CoC) has also recognized the value of the CAP cancer protocols and has mandated that pathologists at CoC-approved cancer programs include the required data elements of the cancer protocols in their surgical pathology reports on cancer specimens.

mTuitive's unique method of capturing and reporting structured information provides valuable data for pathology, surgery, oncology, and cancer staging applications. “We believe in and are committed to what the CAP is doing in cancer care and, through our collaboration, eFRM furthers how information technology can improve care for cancer patients,” said John Murphy, CEO, mTuitive.

The CAP and mTuitive will offer two versions of eFRM. The first is a basic, standalone version; the second includes a wider range of functionality and was designed to be integrated within a laboratory information system. Both versions will facilitate broader adoption among pathologists and help simplify the management of content changes to the cancer protocols.

Related Links:

College of American Pathologists (CAP)
mTuitive



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
New
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
HPV Molecular Test
BD Onclarity HPV Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: New findings demonstrate that anti-Müllerian hormone (AMH) may help identify which breast cancer patients are most likely to benefit from chemotherapy plus endocrine therapy (Image Credit: Shutterstock)

AMH Test Helps Predict Adjuvant Chemotherapy Benefit in Premenopausal Breast Cancer

Hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer can present a difficult treatment decision in premenopausal patients with low recurrence scores.... Read more

Molecular Diagnostics

view channel
Image Credit: iStock

Sequencing-Based Newborn Screening Identifies Pediatric Cancer Risk at Birth

Newborn screening in the United States relies on heel-stick blood spots to identify rare, treatable disorders through biochemical testing, but these programs generally do not assess inherited cancer risk... Read more

Microbiology

view channel
Image: The QIAstat-Dx BCID GPF Plus AMR Panel is the first QIAstat-Dx panel for bloodstream infections to receive FDA clearance (Photo courtesy of Qiagen)

FDA Clears One-Hour Panel for Bloodstream Infection and AMR Detection

Bloodstream infections can rapidly progress to sepsis, a life-threatening condition affecting an estimated 1.7 million adults in the U.S. each year. Rapid identification of pathogens and antimicrobial... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.